DIM Sartorius Stedim Biotech SA

Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech SA / Key word(s): AGM/EGM
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.

25-March-2025 / 15:35 CET/CEST


Aubagne, France | March 25, 2025

Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.

At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority.

The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed for three years while Joachim Kreuzburg was reappointed for two years and René Fáber, Pascale Boissel and Lothar Kappich for four years.

Henri Riey, who served on the Board since 2007, decided not to seek re-election. The Board sincerely thanked him for his valuable contributions and expertise over nearly two decades.

Effective March 25, 2025, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of: Joachim Kreuzburg (Chairman), René Fáber (CEO), Pascale Boissel, Susan Dexter, Cécile Dussart, Romaine Fernandes (Director Representing Employees), Anne-Marie Graffin (Lead Independent Director), Lothar Kappich, and Christopher Nowers.

The shareholders also approved all other resolutions by a large majority, including the proposal to pay a dividend of 0.69 euros per share for fiscal 2024. The total payout will be 67.1 million euros. The dividend will be paid as from April 4, 2025.


Further Information





Financial calendar
April 16, 2025                     Publication of the first quarter results January to March 2025
July 22, 2025                       Publication of the half-year results January to June 2025
October 16, 2025             Publication of the nine-month results January to September 2025


A profile of Sartorius Stedim Biotech 
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe.  
 
Visit our and follow us on .


Contact
Leona Malorny
Head of External Communications
7

 

Attachment

File:


Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:
E-mail:
Internet:
ISIN: FR0013154002
EQS News ID: 2105416

 
End of Announcement - EQS News Service

2105416  25-March-2025 CET/CEST

EN
25/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sartorius Stedim Biotech SA

 PRESS RELEASE

Résolutions de l’Assemblée générale annuelle mixte des actionnaires de...

Sartorius Stedim Biotech SA / Mot-clé(s) : Assemblée générale Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A. 25-Mars-2025 / 15:35 CET/CEST Aubagne, le 25 mars 2025 Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A.Lors de l'Assemblée générale annuelle mixte de Sartorius Stedim Biotech S.A. qui s'est tenue aujourd'hui, les actionnaires à une large majorité ont donné décharge à tous les administrateurs.Les actionnaires ont élu Cécile Dussart et Christopher Nowers en tant que nouve...

 PRESS RELEASE

Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius ...

Sartorius Stedim Biotech SA / Key word(s): AGM/EGM Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. 25-March-2025 / 15:35 CET/CEST Aubagne, France | March 25, 2025 Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority.The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed...

 PRESS RELEASE

Sartorius Stedim Biotech releases Universal Registration Document 2024

Sartorius Stedim Biotech SA / Key word(s): Annual Results Sartorius Stedim Biotech releases Universal Registration Document 2024 17-Feb-2025 / 10:02 CET/CEST Aubagne, France | February 17, 2025 Sartorius Stedim Biotech releases Universal Registration Document 2024Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2024 including the Annual Financial Report. The document is available at the following link: Financial calendar March 25, 2025               Annual Shareholders’ Meeting  April 16, 2025                 ...

 PRESS RELEASE

Sartorius Stedim Biotech publie son Document d’Enregistrement Universe...

Sartorius Stedim Biotech SA / Mot-clé(s) : Résultat annuel Sartorius Stedim Biotech publie son Document d’Enregistrement Universel 2024 17-Fév-2025 / 10:02 CET/CEST Aubagne, le 17 février 2025 Sartorius Stedim Biotech publie son Document d’Enregistrement Universel 2024Sartorius Stedim Biotech, partenaire de premier plan de l’industrie biopharmaceutique, a publié aujourd’hui son Document d‘Enregistrement Universel 2024 incluant le rapport financier annuel. Le document est disponible à l’adresse suivante : Agenda financier  25 mars 2025                  Assemblée générale annuelle de...

 PRESS RELEASE

Le Conseil d’administration de Sartorius Stedim Biotech décide de prop...

Sartorius Stedim Biotech SA / Mot-clé(s) : Dividende Le Conseil d’administration de Sartorius Stedim Biotech décide de proposer un dividende de 0,69 euro par action à l’Assemblée générale annuelle des actionnaires 07-Fév-2025 / 15:57 CET/CEST Aubagne, le 7 février 2025 Le Conseil d’administration de Sartorius Stedim Biotech décide de proposer un dividende de 0,69 euro par action à l’Assemblée générale annuelle des actionnaires   Cécile Dussart et Christopher Nowers candidats à l'élection au Conseil d'administration lors de la prochaine Assemblée générale des actionnaires Le Consei...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch